PayerTalkCE™ Presents: Current Strategies to Optimize Clinical, Economic, and Humanistic Outcomes in Multiple Sclerosis

PayerTalkCE™ Presents: Current Strategies to Optimize Clinical, Economic, and Humanistic Outcomes in Multiple Sclerosis is organized by Impact Education, LLC.

Release Date: June 1, 2024
Expiration Date: December 31, 2025

Statement of Need/Program Overview:
Thirty years ago, there were no approved therapies for multiple sclerosis (MS). Today, there are over a dozen disease modifying therapies (DMTs) proven to reduce the frequency of relapses and accumulation of disability reflecting a major advance in the understanding of immune responses that drive the disease. Despite this progress, the limited effectiveness of current therapeutics at controlling neuroinflammation within the central nervous system (CNS) and halting MS progression is a significant unmet need. This PayerTalkCE symposium will include a multidisciplinary faculty discussion to identify mechanisms underlying the neuroinflammation observed in MS and review clinical trial data from emerging MS DMTs that target CNS inflammation. The panel will also assess the importance of considering disease subtype, type and severity of comorbidities, and patient preference when recommending MS treatment.

Educational Objectives:
After completing this activity, the participant should be better able to:

• Explain the role played by neuroinflammation in the development and progression of multiple sclerosis (MS)
• Review the mechanism of action and safety and efficacy data of emerging MS disease-modifying therapies that target neuroinflammation
• Assess the importance of MS subtype, presence of comorbidities, and patient preference when recommending MS treatment